Author

Jocelyn Harris

Observed name: Harris, Jocelyn

Observed institution: Icahn School of Medicine at Mount Sinai

ORCID: 0000-0003-4289-8544

Observed ORCID: 0000-0003-4289-8544

OpenAlex ID: A5044675858

Downregulation of exhausted cytotoxic T cells in gene expression networks of multisystem inflammatory syndrome in children

2021 · Noam D. Beckmann, Phillip H. Comella, et al. · Nature Communications · 74

Molecular states during acute COVID-19 reveal distinct etiologies of long-term sequelae

2022 · Ryan C. Thompson, Nicole W. Simons, et al. · Nature Medicine · 66

PDF

Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR

2022 · Megan Schwarz, Denis Torre, et al. · Nature Biotechnology · 45

PDF

Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

2024 · Edwin Roger Parra, Jiexin Zhang, et al. · Clinical Cancer Research · 41

PDF

Sampling the host response to SARS-CoV-2 in hospitals under siege

2020 · Alexander W. Charney, Nicole W. Simons, et al. · Nature Medicine · 24

PDF

Circulating proteins to predict COVID-19 severity

2023 · Chen-Yang Su, Sirui Zhou, et al. · Scientific Reports · 20

PDF

The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals

2022 · Guillaume Butler-Laporte, Edgar Gonzalez-Kozlova, et al. · Clinical Proteomics · 9

PDF

Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma

2024 · Edgar Gonzalez-Kozlova, Hsin-Hui Huang, et al. · Cancer Research Communications · 3

Circulating proteins to predict adverse COVID-19 outcomes

2021 · Chen-Yang Su, Sirui Zhou, et al. · medRxiv · 3

PDF

Correction: The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals

2022 · Guillaume Butler-Laporte, Edgar Gonzalez-Kozlova, et al. · Clinical Proteomics · 2

PDF

Author Correction: Sampling the host response to SARS-CoV-2 in hospitals under siege

2021 · The Mount Sinai COVID-19 Biobank Team, Alexander W. Charney, et al. · Nature Medicine · 2

PDF

Author Correction: Sampling the host response to SARS-CoV-2 in hospitals under siege

2020 · Alexander W. Charney, Nicole W. Simons, et al. · Nature Medicine · 2

PDF

Supplementary Table 1 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma

2025 · Edgar Gonzalez-Kozlova, Hsin-Hui Huang, et al.

Supplementary Table 2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma

2025 · Edgar Gonzalez-Kozlova, Hsin-Hui Huang, et al.

Supplementary Table 3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma

2025 · Edgar Gonzalez-Kozlova, Hsin-Hui Huang, et al.

Figure S3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma

2025 · Edgar Gonzalez-Kozlova, Hsin-Hui Huang, et al.

Figure S2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma

2025 · Edgar Gonzalez-Kozlova, Hsin-Hui Huang, et al.

PDF

Figure S1 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma

2025 · Edgar Gonzalez-Kozlova, Hsin-Hui Huang, et al.

PDF

Figure S3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma